linagliptin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
dipeptidyl aminopeptidase-IV inhibitors 4175 668270-12-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • linagliptin
  • tradjenta
  • BI 1356
  • BI-1356
Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. Both incretin hormones are involved in the physiological regulation of glucose homeostasis. Incretin hormones are secreted at a low basal level throughout the day and levels rise immediately after meal intake. GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. Furthermore, GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose output.
  • Molecular weight: 472.55
  • Formula: C25H28N8O2
  • CLOGP: 2.19
  • LIPINSKI: 0
  • HAC: 10
  • HDO: 1
  • TPSA: 113.48
  • ALOGS: -3.97
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.90 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 129 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.90 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
May 2, 2011 FDA BOEHRINGER INGELHEIM
July 1, 2011 PMDA Nippon Boehringer Ingelheim Co., Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Subarachnoid haemorrhage 234.59 15.61 102 17325 14181 63457414
Blood glucose increased 224.53 15.61 185 17242 83571 63388024
Pemphigoid 216.67 15.61 80 17347 7264 63464331
Cardiospasm 196.97 15.61 54 17373 1853 63469742
Hypoglycaemia 196.00 15.61 149 17278 59916 63411679
Palmoplantar keratoderma 194.23 15.61 54 17373 1953 63469642
Pruritus genital 192.33 15.61 57 17370 2597 63468998
Sleep terror 178.80 15.61 54 17373 2626 63468969
Atrial tachycardia 158.31 15.61 55 17372 4185 63467410
Carotid artery occlusion 152.84 15.61 55 17372 4639 63466956
Tension headache 147.49 15.61 55 17372 5131 63466464
Pancreatitis 141.13 15.61 113 17314 48942 63422653
Dermatitis bullous 137.20 15.61 60 17367 8448 63463147
Anosmia 132.56 15.61 55 17372 6805 63464790
Immunisation 124.21 15.61 34 17393 1159 63470436
Ventricular tachycardia 106.28 15.61 67 17360 19912 63451683
Pain of skin 104.81 15.61 55 17372 11579 63460016
Vasculitis 104.29 15.61 64 17363 18145 63453450
Facial pain 103.99 15.61 53 17374 10508 63461087
Lip swelling 98.91 15.61 76 17351 30987 63440608
Eye pruritus 97.78 15.61 62 17365 18609 63452986
Angioedema 90.60 15.61 87 17340 47878 63423717
Glycosylated haemoglobin increased 90.53 15.61 51 17376 12347 63459248
Blindness 89.30 15.61 62 17365 21637 63449958
Acute kidney injury 86.76 15.61 210 17217 263205 63208390
Renal impairment 79.27 15.61 109 17318 88246 63383349
Drug ineffective 78.26 15.61 104 17323 1044661 62426934
Muscle twitching 78.14 15.61 55 17372 19613 63451982
Intentional product misuse 73.35 15.61 87 17340 60830 63410765
Hyperglycaemia 71.72 15.61 72 17355 41795 63429800
Euglycaemic diabetic ketoacidosis 69.44 15.61 29 17398 3645 63467950
Hallucination 68.84 15.61 80 17347 54737 63416858
Diplopia 66.80 15.61 54 17373 23674 63447921
Transient ischaemic attack 66.65 15.61 66 17361 37687 63433908
Hyperlactacidaemia 62.42 15.61 25 17402 2824 63468771
Diabetic ketoacidosis 60.56 15.61 48 17379 20457 63451138
Tinnitus 60.52 15.61 61 17366 35567 63436028
Cystostomy 56.61 15.61 11 17416 75 63471520
Dry skin 55.29 15.61 73 17354 56814 63414781
Metabolic acidosis 52.00 15.61 63 17364 45006 63426589
Pancreatic carcinoma 51.98 15.61 30 17397 7598 63463997
Palpitations 51.93 15.61 103 17324 112667 63358928
Diabetes mellitus inadequate control 50.32 15.61 38 17389 15088 63456507
Hyperkalaemia 50.29 15.61 68 17359 54135 63417460
Chronic kidney disease 50.01 15.61 62 17365 45336 63426259
Cardiac failure 47.94 15.61 87 17340 89055 63382540
Dizziness 46.68 15.61 237 17190 429688 63041907
Systemic lupus erythematosus 45.58 15.61 3 17424 208915 63262680
Disturbance in attention 45.06 15.61 54 17373 38135 63433460
Blood glucose abnormal 43.30 15.61 27 17400 7865 63463730
Rash papular 42.64 15.61 35 17392 15667 63455928
Rheumatoid arthritis 42.36 15.61 9 17418 253810 63217785
Drug intolerance 42.19 15.61 16 17411 308645 63162950
Arthropathy 42.00 15.61 7 17420 234785 63236810
Pancreatitis acute 41.60 15.61 44 17383 27122 63444473
Glomerular filtration rate decreased 40.84 15.61 32 17395 13409 63458186
Muscular weakness 40.65 15.61 98 17329 122255 63349340
Lactic acidosis 40.11 15.61 51 17376 38236 63433359
Cognitive disorder 40.06 15.61 62 17365 55753 63415842
Contraindicated product administered 40.04 15.61 6 17421 217642 63253953
Hyperhidrosis 39.79 15.61 90 17337 107746 63363849
Dehydration 37.81 15.61 119 17308 173235 63298360
Diabetic metabolic decompensation 37.44 15.61 15 17412 1695 63469900
Infusion related reaction 36.55 15.61 11 17416 245510 63226085
Pemphigus 36.36 15.61 4 17423 183722 63287873
Therapeutic product effect decreased 36.29 15.61 5 17422 193182 63278413
Amnesia 36.11 15.61 59 17368 55526 63416069
Wound 33.75 15.61 3 17424 163260 63308335
Hypoglycaemic encephalopathy 32.98 15.61 9 17418 303 63471292
Myocardial infarction 31.04 15.61 78 17349 99815 63371780
Drug hypersensitivity 30.96 15.61 24 17403 310663 63160932
Memory impairment 30.93 15.61 80 17347 104178 63367417
Glossodynia 30.54 15.61 6 17421 178870 63292725
Pain 29.87 15.61 104 17323 740524 62731071
Renal failure 29.63 15.61 85 17342 117567 63354028
Pruritus 29.07 15.61 184 17243 361269 63110326
Visual impairment 27.35 15.61 67 17360 84379 63387216
Abdominal pain upper 26.07 15.61 119 17308 206325 63265270
Discomfort 25.82 15.61 7 17420 167367 63304228
Blood glucose decreased 25.32 15.61 30 17397 20922 63450673
Urine calcium/creatinine ratio increased 25.26 15.61 6 17421 114 63471481
Rhabdomyolysis 25.03 15.61 44 17383 43907 63427688
Joint swelling 24.97 15.61 32 17395 327634 63143961
Mucosal membrane hyperplasia 24.71 15.61 5 17422 43 63471552
Vomiting 24.18 15.61 247 17180 559370 62912225
Shock 24.17 15.61 31 17396 23432 63448163
Ketoacidosis 24.07 15.61 15 17412 4363 63467232
Feeling abnormal 23.77 15.61 92 17335 148300 63323295
Heart rate increased 22.68 15.61 67 17360 94171 63377424
Insulin-like growth factor decreased 22.27 15.61 7 17420 389 63471206
Sinusitis 21.95 15.61 18 17409 226635 63244960
Hypersensitivity 21.87 15.61 29 17398 292656 63178939
Product use in unapproved indication 21.73 15.61 11 17416 179069 63292526
Urethral caruncle 21.63 15.61 5 17422 84 63471511
Albuminuria 21.06 15.61 6 17421 237 63471358
Bite 20.93 15.61 7 17420 474 63471121
Lethargy 20.93 15.61 47 17380 55960 63415635
Altered state of consciousness 20.92 15.61 30 17397 25200 63446395
Tachycardia 20.36 15.61 75 17352 118081 63353514
Urinary tract infection 20.18 15.61 133 17294 264551 63207044
Chest pain 19.92 15.61 114 17313 215845 63255750
Hypomagnesaemia 19.33 15.61 31 17396 28706 63442889
Parathyroid hyperplasia 19.11 15.61 5 17422 143 63471452
Blood creatinine increased 18.85 15.61 60 17367 87784 63383811
Lipase increased 18.76 15.61 18 17409 9882 63461713
COVID-19 18.00 15.61 70 17357 113033 63358562
Post procedural infection 17.73 15.61 17 17410 9325 63462270
Malaise 17.64 15.61 183 17244 415771 63055824
Pyelonephritis 17.55 15.61 23 17404 17755 63453840
Condition aggravated 17.17 15.61 55 17372 402162 63069433
Back pain 16.78 15.61 127 17300 264018 63207577
Toxic encephalopathy 16.48 15.61 14 17413 6565 63465030
Intentional product use issue 16.33 15.61 74 17353 127818 63343777
Product use issue 16.31 15.61 22 17405 220498 63251097
Bronchitis 16.19 15.61 7 17420 124928 63346667
Helicobacter infection 16.07 15.61 3 17424 92782 63378813
Staphylococcal sepsis 15.82 15.61 15 17412 8113 63463482

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 495.32 15.30 190 21288 8476 34926977
Cardiospasm 204.81 15.30 64 21414 1524 34933929
Palmoplantar keratoderma 187.82 15.30 63 21415 1890 34933563
Pruritus genital 180.36 15.30 63 21415 2141 34933312
Sleep terror 177.25 15.30 63 21415 2255 34933198
Blood glucose increased 174.74 15.30 210 21268 66508 34868945
Dermatitis bullous 170.99 15.30 84 21394 6838 34928615
Tension headache 167.64 15.30 65 21413 2977 34932476
Facial pain 155.25 15.30 65 21413 3639 34931814
Atrial tachycardia 152.90 15.30 64 21414 3581 34931872
Carotid artery occlusion 151.36 15.30 64 21414 3673 34931780
Anosmia 146.80 15.30 64 21414 3960 34931493
Pancreatitis 146.14 15.30 148 21330 38743 34896710
Hypoglycaemia 141.40 15.30 171 21307 54469 34880984
Immunisation 137.19 15.30 43 21435 1034 34934419
Glycosylated haemoglobin increased 119.79 15.30 79 21399 11281 34924172
Pain of skin 115.71 15.30 62 21416 6047 34929406
Eye pruritus 106.54 15.30 63 21415 7426 34928027
Subarachnoid haemorrhage 94 15.30 71 21407 12564 34922889
Lip swelling 93.15 15.30 78 21400 16002 34919451
Muscle twitching 92.83 15.30 65 21413 10233 34925220
Pericarditis 87.88 15.30 66 21412 11579 34923874
Vasculitis 87.43 15.30 65 21413 11231 34924222
Blood mercury abnormal 78.86 15.30 20 21458 214 34935239
5-hydroxyindolacetic acid in urine increased 77.00 15.30 20 21458 237 34935216
Ventricular tachycardia 76.67 15.30 88 21390 26491 34908962
Blindness 69.36 15.30 64 21414 14922 34920531
Rash papular 68.26 15.30 54 21424 10224 34925229
Migraine 66.48 15.30 67 21411 17411 34918042
Pericardial disease 65.91 15.30 20 21458 430 34935023
Diplopia 64.86 15.30 65 21413 16778 34918675
Pulmonary valve disease 62.27 15.30 18 21460 325 34935128
Cardiac failure 62.01 15.30 158 21320 91090 34844363
Dry skin 60.68 15.30 85 21393 31202 34904251
Left ventricular dysfunction 58.90 15.30 49 21429 9958 34925495
Alopecia 57.73 15.30 73 21405 24282 34911171
Tinnitus 56.99 15.30 66 21412 20052 34915401
Drug ineffective 55.93 15.30 124 21354 456627 34478826
Euglycaemic diabetic ketoacidosis 50.84 15.30 29 21449 3193 34932260
Palpitations 48.94 15.30 88 21390 39898 34895555
Cerebral infarction 47.98 15.30 71 21407 27384 34908069
Visual impairment 47.98 15.30 82 21396 35720 34899733
Low density lipoprotein decreased 47.69 15.30 20 21458 1123 34934330
Physical examination abnormal 45.92 15.30 14 21464 306 34935147
Diabetic ketoacidosis 45.86 15.30 56 21422 17976 34917477
Transient ischaemic attack 44.83 15.30 69 21409 27544 34907909
Cognitive disorder 44.22 15.30 70 21408 28623 34906830
Abdominal discomfort 44.19 15.30 107 21371 59728 34875725
Diastolic dysfunction 44.12 15.30 34 21444 6193 34929260
Amnesia 44.00 15.30 67 21411 26496 34908957
Disturbance in attention 43.77 15.30 66 21412 25879 34909574
Ventricular hyperkinesia 42.19 15.30 12 21466 204 34935249
Hepatic neoplasm 40.07 15.30 21 21457 1956 34933497
Right atrial enlargement 39.86 15.30 12 21466 251 34935202
Stenosis 39.75 15.30 19 21459 1454 34933999
Mean platelet volume increased 38.98 15.30 14 21464 516 34934937
Angioedema 37.99 15.30 76 21402 37298 34898155
Hypochromasia 37.50 15.30 12 21466 309 34935144
Electrocardiogram Q wave abnormal 37.37 15.30 13 21465 436 34935017
Cardiac discomfort 36.93 15.30 14 21464 602 34934851
Hyperglycaemia 36.27 15.30 77 21401 39403 34896050
Diabetic nephropathy 35.87 15.30 20 21458 2108 34933345
Product use in unapproved indication 35.31 15.30 14 21464 117485 34817968
Mitral valve thickening 35.09 15.30 12 21466 382 34935071
Pruritus 34.95 15.30 176 21302 141805 34793648
Rales 34.17 15.30 36 21442 9847 34925606
Hepatojugular reflux 33.67 15.30 13 21465 588 34934865
Completed suicide 32.41 15.30 10 21468 98158 34837295
Pancreatic carcinoma 31.80 15.30 33 21445 8868 34926585
Drug abuse 31.12 15.30 11 21467 99085 34836368
Tricuspid valve incompetence 31.01 15.30 34 21444 9726 34925727
Aortic valve incompetence 30.84 15.30 27 21451 5877 34929576
Blood glucose abnormal 30.65 15.30 27 21451 5925 34929528
Renal impairment 30.56 15.30 127 21351 94386 34841067
Dehydration 30.50 15.30 159 21319 129810 34805643
Memory impairment 29.37 15.30 75 21403 43243 34892210
Occult blood 29.05 15.30 13 21465 855 34934598
Death 29.03 15.30 136 21342 397913 34537540
Abdominal pain upper 28.79 15.30 103 21375 71387 34864066
Mitral valve disease 28.55 15.30 15 21463 1404 34934049
Left ventricular enlargement 28.34 15.30 12 21466 690 34934763
Expired product administered 27.59 15.30 20 21458 3321 34932132
Helicobacter gastritis 27.56 15.30 14 21464 1222 34934231
Necrotising oesophagitis 27.35 15.30 11 21467 555 34934898
Haemoglobin increased 27.23 15.30 20 21458 3389 34932064
Pancreatitis acute 27.14 15.30 56 21422 28085 34907368
Bundle branch block left 26.63 15.30 25 21453 5954 34929499
Mucosal dryness 26.59 15.30 14 21464 1317 34934136
Echocardiogram abnormal 26.54 15.30 13 21465 1050 34934403
Acute kidney injury 26.07 15.30 294 21184 304694 34630759
Hypoglycaemic coma 25.84 15.30 17 21461 2414 34933039
Hypovolaemia 25.65 15.30 30 21448 9204 34926249
Haematocrit increased 25.49 15.30 16 21462 2097 34933356
Left atrial enlargement 25.42 15.30 12 21466 893 34934560
Mitral valve incompetence 25.18 15.30 38 21440 14905 34920548
Dyspnoea at rest 25.17 15.30 20 21458 3808 34931645
Hallucination 24.98 15.30 79 21399 51419 34884034
Hypohidrosis 24.78 15.30 8 21470 212 34935241
Neoplasm 24.62 15.30 23 21455 5444 34930009
Chronic kidney disease 24.54 15.30 68 21410 41142 34894311
Pericardial haemorrhage 24.04 15.30 18 21460 3140 34932313
Peak expiratory flow rate decreased 23.93 15.30 7 21471 132 34935321
Bronchitis viral 23.29 15.30 8 21470 258 34935195
Blood iron decreased 23.25 15.30 22 21456 5291 34930162
Ventricular arrhythmia 22.51 15.30 22 21456 5506 34929947
Acute lung injury 22.25 15.30 13 21465 1497 34933956
Neutropenia 22.14 15.30 39 21439 156739 34778714
Heart rate increased 21.48 15.30 70 21408 46273 34889180
Left atrial dilatation 21.32 15.30 14 21464 1982 34933471
Poikilocytosis 21.29 15.30 7 21471 197 34935256
Disease progression 21.28 15.30 21 21457 108056 34827397
Intentional product misuse 21.24 15.30 69 21409 45542 34889911
General physical health deterioration 20.88 15.30 29 21449 128240 34807213
Hyperkalaemia 20.69 15.30 91 21387 69298 34866155
Carotid artery stenosis 20.48 15.30 20 21458 4999 34930454
Left ventricular hypertrophy 20.27 15.30 25 21453 8105 34927348
Depression 20.13 15.30 18 21460 97080 34838373
Carotid arteriosclerosis 19.77 15.30 13 21465 1845 34933608
Febrile neutropenia 19.36 15.30 34 21444 136815 34798638
Diabetic ketoacidotic hyperglycaemic coma 18.92 15.30 6 21472 150 34935303
Tachycardia 18.70 15.30 102 21376 84670 34850783
Eosinophilic pneumonia 18.26 15.30 16 21462 3485 34931968
Chills 18.06 15.30 14 21464 81029 34854424
Seizure 17.78 15.30 23 21455 104834 34830619
Electrocardiogram T wave inversion 17.62 15.30 13 21465 2218 34933235
Amylase increased 17.60 15.30 20 21458 5948 34929505
Hyperaesthesia teeth 17.49 15.30 8 21470 554 34934899
Pancytopenia 17.05 15.30 20 21458 95137 34840316
Supraventricular tachycardia 16.95 15.30 27 21451 11090 34924363
Diabetes mellitus inadequate control 16.93 15.30 30 21448 13434 34922019
Hypertensive heart disease 16.74 15.30 13 21465 2395 34933058
Toxicity to various agents 16.67 15.30 65 21413 200297 34735156
Lactic acidosis 16.54 15.30 53 21425 34719 34900734
Glomerular filtration rate decreased 16.45 15.30 29 21449 12932 34922521
Muscular weakness 16.27 15.30 88 21390 72809 34862644
Somnolence 16.26 15.30 27 21451 111089 34824364
Chest pain 16.13 15.30 133 21345 126629 34808824
Anaemia macrocytic 16.13 15.30 14 21464 3012 34932441
Interstitial lung disease 16.08 15.30 81 21397 65201 34870252
Feeling abnormal 15.96 15.30 79 21399 63156 34872297
Off label use 15.95 15.30 173 21305 419351 34516102
Bronchial hyperreactivity 15.89 15.30 11 21467 1698 34933755
Malaise 15.76 15.30 179 21299 185646 34749807
Blindness transient 15.43 15.30 12 21466 2214 34933239
Respiratory symptom 15.39 15.30 11 21467 1786 34933667
Systolic dysfunction 15.39 15.30 13 21465 2695 34932758
Red blood cell count decreased 15.38 15.30 46 21432 29044 34906409

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 683.21 13.71 258 35798 15057 79693275
Cardiospasm 377.61 13.71 113 35943 3188 79705144
Palmoplantar keratoderma 360.21 13.71 112 35944 3604 79704728
Pruritus genital 351.54 13.71 115 35941 4371 79703961
Sleep terror 340.15 13.71 112 35944 4346 79703986
Blood glucose increased 312.72 13.71 319 35737 114656 79593676
Tension headache 298.19 13.71 115 35941 7096 79701236
Atrial tachycardia 295.83 13.71 114 35942 7019 79701313
Subarachnoid haemorrhage 295.01 13.71 166 35890 24299 79684033
Hypoglycaemia 292.98 13.71 291 35765 101303 79607029
Carotid artery occlusion 288.13 13.71 114 35942 7533 79700799
Anosmia 272.09 13.71 114 35942 8730 79699602
Immunisation 242.75 13.71 73 35983 2094 79706238
Facial pain 238.63 13.71 115 35941 12235 79696097
Dermatitis bullous 237.60 13.71 120 35936 14125 79694207
Pain of skin 217.44 13.71 114 35942 14499 79693833
Eye pruritus 191.26 13.71 118 35938 20452 79687880
Pancreatitis 183.98 13.71 189 35867 68386 79639946
Vasculitis 176.88 13.71 121 35935 24981 79683351
Ventricular tachycardia 175.31 13.71 148 35908 41787 79666545
Glycosylated haemoglobin increased 167.75 13.71 106 35950 19154 79689178
Muscle twitching 166.55 13.71 116 35940 24648 79683684
Blindness 163.49 13.71 121 35935 28262 79680070
Lip swelling 156.01 13.71 137 35919 40774 79667558
Drug ineffective 136.42 13.71 174 35882 1080739 78627593
Diplopia 129.46 13.71 113 35943 33353 79674979
Dry skin 117.10 13.71 149 35907 67846 79640486
Tinnitus 116.72 13.71 121 35935 44212 79664120
Euglycaemic diabetic ketoacidosis 115.12 13.71 58 35998 6786 79701546
Cardiac failure 112.74 13.71 229 35827 154613 79553719
Acute kidney injury 112.15 13.71 498 35558 518906 79189426
Rash papular 109.83 13.71 86 35970 21830 79686502
Transient ischaemic attack 109.50 13.71 127 35929 52568 79655764
Angioedema 108.51 13.71 152 35904 75883 79632449
Diabetic ketoacidosis 106.19 13.71 102 35954 34020 79674312
Disturbance in attention 93.33 13.71 115 35941 50686 79657646
Hallucination 90.54 13.71 149 35907 85596 79622736
Renal impairment 86.18 13.71 208 35848 157575 79550757
Hyperglycaemia 84.98 13.71 130 35926 70205 79638127
Blood mercury abnormal 84.95 13.71 20 36036 214 79708118
5-hydroxyindolacetic acid in urine increased 82.93 13.71 20 36036 239 79708093
Chronic kidney disease 80.95 13.71 123 35933 66031 79642301
Intentional product misuse 80.50 13.71 150 35906 95015 79613317
Palpitations 80.24 13.71 177 35879 126433 79581899
Cognitive disorder 79.95 13.71 126 35930 69800 79638532
Amnesia 76.81 13.71 117 35939 62940 79645392
Pancreatic carcinoma 71.77 13.71 55 36001 13522 79694810
Dehydration 70.99 13.71 260 35796 247927 79460405
Pulmonary valve disease 69.66 13.71 18 36038 290 79708042
Pericardial disease 66.72 13.71 20 36036 567 79707765
Visual impairment 66.70 13.71 136 35920 91995 79616337
Hyperkalaemia 65.89 13.71 154 35902 114244 79594088
Product use in unapproved indication 62.23 13.71 18 36038 250341 79457991
Hyperlactacidaemia 62.14 13.71 36 36020 5559 79702773
Diabetes mellitus inadequate control 61.66 13.71 65 35991 24199 79684133
Memory impairment 56.43 13.71 143 35913 111591 79596741
Metabolic acidosis 56.42 13.71 119 35937 82410 79625922
Therapeutic product effect decreased 55.68 13.71 5 36051 163858 79544474
Completed suicide 55.25 13.71 21 36035 245746 79462586
Infusion related reaction 54.61 13.71 18 36038 230219 79478113
Cerebral infarction 54.56 13.71 84 35972 45592 79662740
Arthropathy 53.72 13.71 8 36048 177103 79531229
Synovitis 52.87 13.71 4 36052 150730 79557602
Migraine 52.81 13.71 120 35936 87373 79620959
Low density lipoprotein decreased 52.35 13.71 20 36036 1201 79707131
Drug hypersensitivity 51.67 13.71 36 36020 298880 79409452
Treatment failure 51.03 13.71 8 36048 170478 79537854
Glomerular filtration rate decreased 51.01 13.71 57 35999 22645 79685687
Muscular weakness 50.73 13.71 174 35882 160555 79547777
Physical examination abnormal 50.64 13.71 14 36042 295 79708037
Pruritus 50.43 13.71 328 35728 394320 79314012
Rheumatoid arthritis 49.97 13.71 16 36040 208454 79499878
Lactic acidosis 49.90 13.71 103 35953 70256 79638076
Left ventricular dysfunction 47.66 13.71 51 36005 19310 79689022
Cystostomy 44.87 13.71 10 36046 82 79708250
Pancreatitis acute 42.94 13.71 79 35977 49525 79658807
Hyperhidrosis 42.67 13.71 158 35898 151334 79556998
Ventricular hyperkinesia 41.97 13.71 12 36044 287 79708045
Blood glucose abnormal 41.50 13.71 36 36020 10530 79697802
Diabetic nephropathy 41.03 13.71 22 36034 2925 79705407
Drug intolerance 40.35 13.71 36 36020 264083 79444249
Diastolic dysfunction 38.80 13.71 35 36021 10776 79697556
Right atrial enlargement 38.67 13.71 12 36044 383 79707949
Mitral valve thickening 37.75 13.71 12 36044 415 79707917
Depression 37.59 13.71 26 36030 216764 79491568
Electrocardiogram Q wave abnormal 36.96 13.71 13 36043 617 79707715
Heart rate increased 36.61 13.71 129 35927 120595 79587737
Hepatojugular reflux 36.60 13.71 13 36043 635 79707697
Stenosis 36.32 13.71 19 36037 2403 79705929
Systemic lupus erythematosus 35.54 13.71 6 36050 121143 79587189
Hepatic neoplasm 35.30 13.71 21 36035 3405 79704927
Haemoglobin increased 34.98 13.71 26 36030 6106 79702226
Pericarditis 34.78 13.71 115 35941 104121 79604211
Cardiac discomfort 34.32 13.71 15 36041 1273 79707059
Abdominal pain upper 34.22 13.71 195 35861 223624 79484708
Tachycardia 34.15 13.71 165 35891 177603 79530729
Renal failure 34.02 13.71 180 35876 200788 79507544
Hypoglycaemic coma 33.65 13.71 23 36033 4737 79703595
Myocardial infarction 33.30 13.71 168 35888 183961 79524371
Hypersensitivity 33.06 13.71 42 36014 262197 79446135
Mean platelet volume increased 32.98 13.71 14 36042 1106 79707226
COVID-19 32.21 13.71 149 35907 157525 79550807
Hypochromasia 32.01 13.71 12 36044 684 79707648
Sinusitis 31.88 13.71 25 36031 195476 79512856
Blood iron decreased 31.71 13.71 37 36019 15397 79692935
Contraindicated product administered 31.38 13.71 16 36040 157522 79550810
Ketoacidosis 31.33 13.71 27 36029 7827 79700505
Left ventricular enlargement 31.20 13.71 12 36044 734 79707598
Feeling abnormal 30.74 13.71 148 35908 159051 79549281
Aortic valve incompetence 30.61 13.71 29 36027 9501 79698831
Left ventricular hypertrophy 30.26 13.71 31 36025 11160 79697172
Neutropenia 29.58 13.71 53 36003 287657 79420675
Wound 29.50 13.71 8 36048 116171 79592161
Pain 28.93 13.71 193 35863 703609 79004723
Toxicity to various agents 28.20 13.71 97 35959 421443 79286889
Diabetic metabolic decompensation 28.16 13.71 18 36038 3314 79705018
Chest pain 27.53 13.71 220 35836 282084 79426248
Haematocrit increased 27.35 13.71 19 36037 4015 79704317
Dizziness 27.17 13.71 360 35696 526081 79182251
Pain in extremity 27.10 13.71 80 35976 364458 79343874
Hepatic enzyme increased 26.57 13.71 26 36030 182584 79525748
Interstitial lung disease 26.48 13.71 111 35945 112489 79595843
Glossodynia 26.46 13.71 7 36049 103330 79605002
Altered state of consciousness 26.31 13.71 60 35996 43762 79664570
Tricuspid valve incompetence 26.03 13.71 38 36018 19674 79688658
Left atrial enlargement 25.67 13.71 12 36044 1191 79707141
Expired product administered 25.64 13.71 23 36033 7028 79701304
Hypoglycaemic encephalopathy 25.40 13.71 10 36046 651 79707681
Haemodynamic instability 25.15 13.71 35 36021 17347 79690985
Hypohidrosis 24.83 13.71 8 36048 289 79708043
End stage renal disease 24.61 13.71 29 36027 12191 79696141
Occult blood 24.37 13.71 13 36043 1710 79706622
Chills 24.26 13.71 22 36034 160212 79548120
Rales 24.18 13.71 37 36019 19964 79688368
Swelling 24.04 13.71 38 36018 216673 79491659
Drug abuse 23.86 13.71 23 36033 162668 79545664
Lipase increased 23.59 13.71 33 36023 16433 79691899
Necrotising oesophagitis 23.44 13.71 11 36045 1102 79707230
Pericardial haemorrhage 23.30 13.71 18 36038 4477 79703855
Helicobacter gastritis 22.63 13.71 14 36042 2435 79705897
Diabetic ketoacidotic hyperglycaemic coma 22.60 13.71 7 36049 222 79708110
Therapy non-responder 22.25 13.71 7 36049 92298 79616034
General physical health deterioration 22.23 13.71 58 35998 275180 79433152
Mucosal membrane hyperplasia 22.12 13.71 5 36051 44 79708288
Diabetic foot 22.07 13.71 16 36040 3616 79704716
Hepatic function abnormal 22.05 13.71 78 35978 73029 79635303
Contusion 21.85 13.71 21 36035 148755 79559577
Carotid arteriosclerosis 21.59 13.71 14 36042 2642 79705690
Mitral valve disease 21.54 13.71 15 36041 3182 79705150
Echocardiogram abnormal 21.26 13.71 13 36043 2215 79706117
Ventricular arrhythmia 21.25 13.71 23 36033 8817 79699515
Urine calcium/creatinine ratio increased 21.04 13.71 6 36050 142 79708190
Bundle branch block left 21.03 13.71 26 36030 11487 79696845
Joint swelling 20.97 13.71 64 35992 288582 79419750
Neoplasm 20.67 13.71 23 36033 9093 79699239
Discomfort 20.55 13.71 16 36040 125601 79582731
Penile oedema 20.32 13.71 7 36049 312 79708020
Amylase increased 19.97 13.71 25 36031 11184 79697148
Urethral caruncle 19.74 13.71 5 36051 74 79708258
Intentional product use issue 19.72 13.71 127 35929 151985 79556347
Psoriasis 19.55 13.71 8 36048 89579 79618753
Product use issue 19.51 13.71 41 36015 209781 79498551
Poikilocytosis 19.42 13.71 7 36049 357 79707975
Left atrial dilatation 19.41 13.71 14 36042 3139 79705193
Malaise 19.37 13.71 320 35736 489549 79218783
Dyspnoea at rest 19.33 13.71 20 36036 7282 79701050
Renal disorder 19.30 13.71 52 36004 42053 79666279
Mitral valve incompetence 19.29 13.71 41 36015 28524 79679808
Back pain 19.12 13.71 216 35840 303964 79404368
Hypovolaemia 19.00 13.71 31 36025 17660 79690672
Psoriatic arthropathy 18.65 13.71 6 36050 77993 79630339
Pemphigus 18.54 13.71 11 36045 99571 79608761
Pancytopenia 18.44 13.71 29 36027 165716 79542616
Peak expiratory flow rate decreased 18.35 13.71 8 36048 675 79707657
Marasmus 18.14 13.71 9 36047 1019 79707313
Nasopharyngitis 17.93 13.71 57 35999 253824 79454508
Mucosal dryness 17.90 13.71 14 36042 3545 79704787
Product dose omission issue 17.89 13.71 55 36001 247482 79460850
Mucosal inflammation 17.75 13.71 6 36050 75574 79632758
Acute myocardial infarction 17.38 13.71 75 35981 76961 79631371
Acute lung injury 17.36 13.71 13 36043 3087 79705245
Helicobacter infection 17.32 13.71 5 36051 69699 79638633
Vomiting 17.24 13.71 408 35648 665420 79042912
Condition aggravated 16.95 13.71 145 35911 500979 79207353
Blood creatinine increased 16.86 13.71 124 35932 154933 79553399
Sputum discoloured 16.80 13.71 33 36023 21710 79686622
Bite 16.69 13.71 7 36049 537 79707795
Electrocardiogram T wave inversion 16.59 13.71 16 36040 5356 79702976
Erythema multiforme 16.40 13.71 29 36027 17622 79690710
Carotid artery stenosis 16.35 13.71 20 36036 8738 79699594
Insulin-like growth factor decreased 16.20 13.71 7 36049 578 79707754
Parathyroid hyperplasia 15.70 13.71 5 36051 174 79708158
Epidermolysis 15.68 13.71 8 36048 960 79707372
Diabetes mellitus 15.21 13.71 73 35983 78317 79630015
Systolic dysfunction 15.04 13.71 13 36043 3782 79704550
Coma 15.02 13.71 14 36042 100635 79607697
Gastrointestinal disorder 14.95 13.71 20 36036 122185 79586147
Supraventricular tachycardia 14.91 13.71 31 36025 21239 79687093
Suicidal ideation 14.83 13.71 8 36048 76332 79632000
Flushing 14.75 13.71 11 36045 88257 79620075
Weight increased 14.64 13.71 70 35986 277316 79431016
Pyelonephritis 14.62 13.71 30 36026 20358 79687974
Antibiotic level above therapeutic 14.62 13.71 7 36049 733 79707599
Albuminuria 14.54 13.71 7 36049 742 79707590
Heart rate decreased 14.21 13.71 7 36049 70309 79638023
Bronchitis viral 14.18 13.71 8 36048 1175 79707157
Injection site pain 14.17 13.71 23 36033 129815 79578517
Latent autoimmune diabetes in adults 14.14 13.71 4 36052 92 79708240
Drug ineffective for unapproved indication 14.04 13.71 3 36053 51235 79657097
Immune-mediated myositis 13.99 13.71 12 36044 3455 79704877
Hypertensive heart disease 13.89 13.71 13 36043 4193 79704139
Arthritis 13.85 13.71 19 36037 114861 79593471
Bone pain 13.85 13.71 4 36052 55738 79652594
Folliculitis 13.71 13.71 4 36052 55376 79652956

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BD11 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD19 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD27 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BH05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Dipeptidyl peptidase 4 (DPP-4) inhibitors
MeSH PA D054873 Dipeptidyl-Peptidase IV Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006728 Hormones
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D054795 Incretins
MeSH PA D011480 Protease Inhibitors
FDA MoA N0000175912 Dipeptidyl Peptidase 4 Inhibitors
FDA EPC N0000175913 Dipeptidyl Peptidase 4 Inhibitor
CHEBI has role CHEBI:35526 antidiabetic
CHEBI has role CHEBI:68612 dipeptidyl peptidase-4 inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Pancreatitis contraindication 75694006 DOID:4989
Hypoglycemic disorder contraindication 237630007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.16 Basic
pKa2 6.13 Basic
pKa3 3.79 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONYLUREA
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 10034877 Aug. 5, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 9486526 Aug. 5, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 8853156 March 5, 2031 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Dipeptidyl peptidase 4 Enzyme INHIBITOR IC50 10 CHEMBL CHEMBL
Muscarinic acetylcholine receptor M1 GPCR IC50 6.53 CHEMBL
Prolyl endopeptidase FAP Enzyme IC50 7.05 CHEMBL
Dipeptidyl peptidase 9 Enzyme IC50 4 CHEMBL
Prolyl endopeptidase FAP Enzyme IC50 6.43 CHEMBL
Dipeptidyl peptidase IV Unclassified IC50 5 CHEMBL

External reference:

IDSource
4030725 VUID
N0000182735 NUI
D09566 KEGG_DRUG
4030725 VANDF
C2746078 UMLSCUI
CHEBI:68610 CHEBI
356 PDB_CHEM_ID
CHEMBL237500 ChEMBL_ID
D000069476 MESH_DESCRIPTOR_UI
DB08882 DRUGBANK_ID
6318 IUPHAR_LIGAND_ID
9039 INN_ID
3X29ZEJ4R2 UNII
10096344 PUBCHEM_CID
1100699 RXNORM
181237 MMSL
27861 MMSL
d07767 MMSL
013732 NDDF
702798009 SNOMEDCT_US
703667006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tradjenta HUMAN PRESCRIPTION DRUG LABEL 1 0597-0140 TABLET, FILM COATED 5 mg ORAL NDA 33 sections
Tradjenta HUMAN PRESCRIPTION DRUG LABEL 1 0597-0140 TABLET, FILM COATED 5 mg ORAL NDA 33 sections
Tradjenta HUMAN PRESCRIPTION DRUG LABEL 1 0597-0140 TABLET, FILM COATED 5 mg ORAL NDA 33 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 0597-0146 TABLET, FILM COATED 2.50 mg ORAL NDA 34 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 0597-0146 TABLET, FILM COATED 2.50 mg ORAL NDA 34 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 0597-0146 TABLET, FILM COATED 2.50 mg ORAL NDA 34 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 0597-0147 TABLET, FILM COATED 2.50 mg ORAL NDA 34 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 0597-0147 TABLET, FILM COATED 2.50 mg ORAL NDA 34 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 0597-0147 TABLET, FILM COATED 2.50 mg ORAL NDA 34 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 0597-0148 TABLET, FILM COATED 2.50 mg ORAL NDA 34 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 0597-0148 TABLET, FILM COATED 2.50 mg ORAL NDA 34 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 0597-0148 TABLET, FILM COATED 2.50 mg ORAL NDA 34 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0164 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0164 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0164 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0182 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0182 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0182 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Jentadueto XR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0270 TABLET, FILM COATED, EXTENDED RELEASE 2.50 mg ORAL NDA 34 sections
Jentadueto XR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0270 TABLET, FILM COATED, EXTENDED RELEASE 2.50 mg ORAL NDA 34 sections
Jentadueto XR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0275 TABLET, FILM COATED, EXTENDED RELEASE 5 mg ORAL NDA 34 sections
Jentadueto XR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0275 TABLET, FILM COATED, EXTENDED RELEASE 5 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0380 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0380 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0385 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0385 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0390 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0390 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0395 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0395 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 34 sections